Descriptive study of stromal expression of CD73 in ductal carcinoma in situ of the breast

This study, to our knowledge, is the first to demonstrate CD73 expression around ductal carcinoma in situ (DCIS). We found a statistically significant difference in the stromal expression of CD73 based on the grade of DCIS. Additionally, there is a link between necrosis and intermediate-grade lesions, but not with high-grade lesions. These findings need further confirmation, as our analysis was limited to only 28 cases. Future research could explore the role of chemoprevention using anti-CD73 agents to potentially prevent the progression of DCIS to invasive breast cancer, which may be beneficial for patients who are unable or unwilling to undergo surgery.